Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2.

Liu W, Baer MR, Bowman MJ, Pera P, Zheng X, Morgan J, Pandey RA, Oseroff AR.

Clin Cancer Res. 2007 Apr 15;13(8):2463-70.

2.
3.

Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.

Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E, Traxler P.

Cancer Res. 2004 Apr 1;64(7):2333-7.

4.

ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy.

Robey RW, Steadman K, Polgar O, Bates SE.

Cancer Biol Ther. 2005 Feb;4(2):187-94. Epub 2005 Feb 8.

PMID:
15684613
5.

Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps.

Burger H, van Tol H, Brok M, Wiemer EA, de Bruijn EA, Guetens G, de Boeck G, Sparreboom A, Verweij J, Nooter K.

Cancer Biol Ther. 2005 Jul;4(7):747-52. Epub 2005 Jul 9.

PMID:
15970668
6.

Imatinib-mediated inactivation of Akt regulates ABCG2 function in head and neck squamous cell carcinoma.

Chu TS, Chen JS, Lopez JP, Pardo FS, Aguilera J, Ongkeko WM.

Arch Otolaryngol Head Neck Surg. 2008 Sep;134(9):979-84. doi: 10.1001/archotol.134.9.979.

PMID:
18794444
7.

Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.

Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE.

Drug Metab Dispos. 2010 Aug;38(8):1371-80. doi: 10.1124/dmd.109.031302. Epub 2010 Apr 27.

8.

Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells.

Kosztyu P, Bukvova R, Dolezel P, Mlejnek P.

Chem Biol Interact. 2014 Aug 5;219:203-10. doi: 10.1016/j.cbi.2014.06.009. Epub 2014 Jun 19.

PMID:
24954033
9.

Improvement of the efficacy of 5-aminolevulinic acid-mediated photodynamic treatment in human oral squamous cell carcinoma HSC-4.

Yamamoto M, Fujita H, Katase N, Inoue K, Nagatsuka H, Utsumi K, Sasaki J, Ohuchi H.

Acta Med Okayama. 2013;67(3):153-64.

10.

Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia.

de Lima LT, Vivona D, Bueno CT, Hirata RD, Hirata MH, Luchessi AD, de Castro FA, de Lourdes F Chauffaille M, Zanichelli MA, Chiattone CS, Hungria VT, Guerra-Shinohara EM.

Med Oncol. 2014 Mar;31(3):851. doi: 10.1007/s12032-014-0851-5. Epub 2014 Jan 29.

PMID:
24469953
11.

Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.

Brendel C, Scharenberg C, Dohse M, Robey RW, Bates SE, Shukla S, Ambudkar SV, Wang Y, Wennemuth G, Burchert A, Boudriot U, Neubauer A.

Leukemia. 2007 Jun;21(6):1267-75. Epub 2007 Mar 22.

PMID:
17519960
12.

ABCG2 transporter inhibitor restores the sensitivity of triple negative breast cancer cells to aminolevulinic acid-mediated photodynamic therapy.

Palasuberniam P, Yang X, Kraus D, Jones P, Myers KA, Chen B.

Sci Rep. 2015 Aug 18;5:13298. doi: 10.1038/srep13298.

13.

Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line.

Skoglund K, Boiso Moreno S, Jönsson JI, Vikingsson S, Carlsson B, Gréen H.

Pharmacogenet Genomics. 2014 Jan;24(1):52-61. doi: 10.1097/FPC.0000000000000022.

PMID:
24322003
14.

Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models.

McDowell HP, Meco D, Riccardi A, Tanno B, Berardi AC, Raschellà G, Riccardi R, Dominici C.

Int J Cancer. 2007 Mar 1;120(5):1141-9.

15.

Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2.

Eadie LN, Saunders VA, Hughes TP, White DL.

Leuk Lymphoma. 2013 Mar;54(3):569-78. doi: 10.3109/10428194.2012.715345. Epub 2012 Aug 21.

PMID:
22845311
16.

Pivotal roles of peptide transporter PEPT1 and ATP-binding cassette (ABC) transporter ABCG2 in 5-aminolevulinic acid (ALA)-based photocytotoxicity of gastric cancer cells in vitro.

Hagiya Y, Endo Y, Yonemura Y, Takahashi K, Ishizuka M, Abe F, Tanaka T, Okura I, Nakajima M, Ishikawa T, Ogura S.

Photodiagnosis Photodyn Ther. 2012 Sep;9(3):204-14. doi: 10.1016/j.pdpdt.2011.12.004. Epub 2012 Jan 4.

PMID:
22959800
17.

Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.

Hiwase DK, Saunders V, Hewett D, Frede A, Zrim S, Dang P, Eadie L, To LB, Melo J, Kumar S, Hughes TP, White DL.

Clin Cancer Res. 2008 Jun 15;14(12):3881-8. doi: 10.1158/1078-0432.CCR-07-5095.

18.

Critical role of ABCG2 in ALA-photodynamic diagnosis and therapy of human brain tumor.

Ishikawa T, Kajimoto Y, Inoue Y, Ikegami Y, Kuroiwa T.

Adv Cancer Res. 2015;125:197-216. doi: 10.1016/bs.acr.2014.11.008. Epub 2015 Jan 8. Review.

PMID:
25640271
19.

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia.

Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE.

Clin Pharmacol Ther. 2008 Feb;83(2):258-64. Epub 2007 Jun 13.

PMID:
17568400

Supplemental Content

Support Center